CN-121991895-A - Human pancreatic cancer cell line PDAC-X6 and application thereof

Abstract

A human pancreatic cancer cell line PDAC-X6 and application thereof belong to the field of microbial animal cell lines. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homosapiens, and is preserved in China Center for Type Culture Collection (CCTCC) at the year 2025, month 11 and day 22, and the preservation number is CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be used in the establishment of a cell model for pancreatic cancer occurrence, development or metastasis. The human pancreatic cancer cell line PDAC-X6 can be applied to a cell model for researching differentiation mechanism, cell morphology and function abnormality of pancreatic cancer and guiding clinical comprehensive diagnosis and treatment. The human pancreatic cancer cell line PDAC-X6 can be applied to researching the occurrence mechanism of pancreatic cancer and screening medicaments for preventing and treating pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied in the establishment of a pancreatic cancer animal model.

Inventors

• XU HAO
• MIAO XIN
• YU CHENG
• SU YUANHUI
• HUANG WEI

Assignees

• 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院）

Dates

Publication Date

20260508

Application Date

20260212

Claims (5)

1. 1. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homosapiens and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of C2025355 at the date of 11 and 22 in 2025.
2. 2. Use of the human pancreatic cancer cell line of claim 1 for the establishment of a cell model for pancreatic carcinogenesis, progression or metastasis.
3. 3. The use of the human pancreatic cancer cell line of claim 1 in studying pancreatic cancer differentiation mechanisms, cell morphology and dysfunction, tumor infiltration and metastasis mechanisms, and cell models that direct clinical integrated diagnosis and treatment.
4. 4. The use of the human pancreatic cancer cell line according to claim 1 for studying the occurrence mechanism of pancreatic cancer and screening drugs for preventing and treating pancreatic cancer.
5. 5. Use of the human pancreatic cancer cell line of claim 1 in the construction of an animal model of pancreatic cancer.

Description

Human pancreatic cancer cell line PDAC-X6 and application thereof Technical Field The invention belongs to the field of microbial animal cell lines, and particularly relates to a human pancreatic cancer cell line PDAC-X6 and application thereof. Background Pancreatic cancer is a malignant solid tumor with extremely poor prognosis, and the incidence rate of the pancreatic cancer is in an annual rising situation at home and abroad. The clinical characteristics of hidden onset, high malignancy, high invasiveness and the like of pancreatic cancer lead to the advanced stage of most patients at the time of treatment, and the patients can not be treated by surgery along with the metastasis of adjacent or distant organs. Chemotherapy, represented by gemcitabine, is still currently the primary treatment regimen for pancreatic cancer patients, but drug resistance issues are prominent, which makes drug treatment limited and patient prognosis still poor. Around the pathogenesis of pancreatic cancer, many fundamental studies have been conducted with open-ended time, but clinical transformation studies of key targets in the relevant pathogenesis, including therapeutic strategy studies, remain relatively slow to develop. Pancreatic cancer requires more transformation studies to drive actual clinical diagnosis and prolong the survival of pancreatic cancer patients. Human tumor cell lines, particularly those with complete data and follow-up, are important tools in tumor biology research. Cell lines from pancreatic primary tumors have tremendous roles in exploring biology and bile duct tumorigenesis, detecting drug sensitivity, developing molecular therapeutic targets, and studying drug resistance mechanisms. A complete pool of tumor cell lines should reflect the diversity of tumor phenotypes and be able to provide cell lines of different tumor heterogeneity, and it is important to use appropriate preclinical models reflecting these characteristics, given the different etiologies of pancreatic tumors and their genetic variations associated with etiology and race. With increased passage in vitro, some of the unique biological characteristics of the cell line change or disappear gradually, and even characteristics that the originating cell does not have. In addition, many cell lines are detected with cross-contamination of cells, the most common sources of contaminating cells being HeLa, T-24 and M14, and erroneous results from studies using these cells. A total of 46 samples of 37 lines of cells were collected from different areas and different laboratories, and each of the samples was subjected to species identification and STR spectrum analysis. The cell cross contamination phenomenon is found to be serious, and the error rate reaches 62.6%. The newly established cell line can maintain the characteristics similar to those of the primary tumor to the greatest extent, and the result obtained by using the cell line for research is closest to the actual condition of a human body. Because of different genetic backgrounds, it is necessary to build a disease model specific to Chinese in order to better study the disease of Chinese. For the above reasons, the continuous establishment of new cell lines and the elimination of old cell lines have become an important link in the study of pancreatic cancer pathogenesis and treatment methods. Disclosure of Invention The invention aims to provide a novel human pancreatic cancer cell line PDAC-X6 and application thereof, aiming at the defects of the number of pancreatic cancer cell lines in the prior art. The invention provides a human pancreatic cancer cell line named as a human pancreatic cancer cell line PDAC-X6 homosapiens, with the preservation number of CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be used as a cell model for the research of the occurrence, development or metastasis mechanism of pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can also be used to model animals of pancreatic cancer. The invention adopts a 78-year-old male surgical excision specimen, is subjected to mixed digestion by type II collagenase/neutral proteinase and then is subjected to primary culture, and a human pancreatic cancer cell line (homo sapiens) is established by cell culture technology, and is named as a human pancreatic cancer cell line PDAC-X6 homo sapiens. The human pancreatic cancer cell line PDAC-X6 homosapiens is preserved in 2025 and 11 months 22, and the preservation unit is China center for type culture Collection (CCTCC for short), the preservation center address is China university of Wuhan and Wuhan, and the preservation center preservation number is CCTCC NO: C2025355. The cell line has the following biological characteristics: 1. the cell grows by adherence, is inhibited in a non-contact way, and can generate superposition growth phenomenon. 2. The cell doubling time was 50.4 h. 3. The immunohistochemical result shows that PDAC-X6 is a medium